MLH1 Promoter Methylation Could Be the Second Hit in Lynch Syndrome Carcinogenesis
Genes · 2023
DOI: 10.3390/genes14112060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2023. Verfasst von Ileana Wanda Carnevali und 7 weiteren Autor:innen. Beteiligte Einrichtung: UO Anatomia Patologica Ospedale di Circolo ASST-Settelaghi, 21100 Varese, Italy. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
(1)
Background
MLH1 hypermethylation is an epigenetic alteration in the tumorigenesis of colorectal cancer (CRC) and endometrial cancer (EC), causing gene silencing, and, as a consequence, microsatellite instability. Commonly, MLH1 hypermethylation is considered a somatic and sporadic event in cancer, and its detection is recognized as a useful tool to distinguish sporadic from inherited conditions (such as, Lynch syndrome (LS)). However, MLH1 hypermethylation has been described in rare cases of CRC and EC in LS patients. (2)
Methods
A total of 61 cancers (31 CRCs, 27 ECs, 2 ovarian cancers, and 1 stomach cancer) from 56 patients referred to cancer genetic counselling were selected for loss of MLH1 protein expression and microsatellite instability. All cases were investigated for MLH1 promoter methylation and MLH1/PMS2 germline variants. (3)
Results
Somatic MLH1 promoter hypermethylation was identified in 16.7% of CRC and in 40% of EC carriers of MLH1 germline pathogenic variants. In two families, primary and secondary MLH1 epimutations were demonstrated. (4)
Conclusions
MLH1 hypermethylation should not be exclusively considered as a sporadic cancer mechanism, as a non-negligible number of LS-related cancers are MLH1 hypermethylated. Current flow charts for universal LS screening, which include MLH1 methylation, should be applied, paying attention to a patient’s family and personal history.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UO Anatomia Patologica Ospedale di Circolo ASST-Settelaghi, 21100 Varese, Italy.
- Centro di Ricerca per lo Studio dei Tumori Eredo-Famigliari, Università dell'Insubria, 21100 Varese, Italy.
- Unit of Functional Oncogenomics and Genetics, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
- Department of Medicine and Thecnological Innovation, Università dell'Insubria, 21100 Varese, Italy.
ORCID-Profile: Ileana Wanda Carnevali, Laura Libera, Alessandra Viel
Zitieren
APA
Carnevali, I. W., Cini, G., Libera, L., Sahnane, N., Facchi, S., Viel, A., Sessa, F., & Tibiletti, M. G. (2023). MLH1 Promoter Methylation Could Be the Second Hit in Lynch Syndrome Carcinogenesis. Genes. https://doi.org/10.3390/genes14112060
Vancouver
Carnevali IW, Cini G, Libera L, Sahnane N, Facchi S, Viel A, et al. MLH1 Promoter Methylation Could Be the Second Hit in Lynch Syndrome Carcinogenesis. Genes. 2023. doi:10.3390/genes14112060
BibTeX
@article{Carnevali2023,
author = {Carnevali, Ileana Wanda and Cini, Giulia and Libera, Laura and Sahnane, Nora and Facchi, Sofia and Viel, Alessandra and Sessa, Fausto and Tibiletti, Maria Grazia},
title = {MLH1 Promoter Methylation Could Be the Second Hit in Lynch Syndrome Carcinogenesis},
journal = {Genes},
year = {2023},
doi = {10.3390/genes14112060}
}
EUVIMED